In non-small cell lung cancer, for example, it has been described that patients with EGFR mutations who have been treated with tyrosine kinase inhibitor (TKI) therapy are more likely to develop leptomeningeal disease (10, 11). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.